News

Canadian biopharmaceutical firm Arbutus Biopharma has identified many molecules that can inhibit the SARS-CoV-2 nsp5 main protease (Mpro), achieving its first milestone under Covid-19 discovery research and license

This deal is part of Merck’s commitment to make the drug available across the globe, following approval for use by regulatory bodies. Merck, in collaboration with Ridgeback Biotherapeutics,

The European Medicines Agency (EMA) has accepted to review Sanofi’s marketing authorization application (MAA) for olipudase alfa to treat acid sphingomyelinase deficiency (ASMD). An investigational enzyme replacement therapy,

Julphar is a pharmaceutical company based in the UAE and has presence in the MENA (Middle East North Africa) region. It will secure exclusive rights to produce and

Merck’s anti-PD-1 therapy, Keytruda, has obtained approval from the US Food and Drug Administration (FDA) as an adjuvant therapy for stage IIB or IIC melanoma patients aged 12

Valneva stated that it is now focused on securing regulatory approvals for VLA2001 after the positive results from the Phase III trial. The firm also added that it

Financial details of the deal have not been disclosed. This deal is part of Sanofi’s strategy to explore growth opportunities and build a vaccines pipeline. The transaction will

  AstraZeneca and Merck & Co (MSD) are together developing and commercialising Lynparza, a first-in-class PARP inhibitor. The sNDA was based on results obtained from the Phase III,

An interleukin-23 (IL-23) inhibitor, Risankizumab is intended to treat patients with Crohn’s disease who have shown insufficient response, lost response or are intolerant to biologic or conventional treatment.